Matthew Winton - 30 Sep 2024 Form 4 Insider Report for Inozyme Pharma, Inc. (INZY)

Role
COO
Signature
/s/ Sanjay Subramanian, as attorney-in-fact for Matthew Winton
Issuer symbol
INZY
Transactions as of
30 Sep 2024
Net transactions value
+$7,610
Form type
4
Filing time
03 Oct 2024, 20:57:02 UTC
Previous filing
03 Apr 2024
Next filing
17 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INZY Common Stock Award $7,610 +1,710 +54% $4.45 4,898 30 Sep 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares purchased pursuant to the Inozyme Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of April 1, 2024 through September 30, 2024. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on September 30, 2024, the last trading day of the purchase period.